You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Original Contributions Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease: A Randomized Trial
Gregg W. Stone; Mark Midei; William Newman; Mark Sanz; James B. Hermiller; Jerome Williams; Naim Farhat; Kenneth W. Mahaffey; Donald E. Cutlip; Peter J. Fitzgerald; Poornima Sood; Xiaolu Su; Alexandra J. Lansky; for the SPIRIT III Investigators
JAMA 2008; 299: 1903-1913.
[Abstract][Full text][PDF]
Editorials Next-Generation Drug-Eluting Stents: A Spirited Step Forward or More of the Same
Original Contributions Efficacy and Safety of Pyridoxal 5'-Phosphate (MC-1) in High-Risk Patients Undergoing Coronary Artery Bypass Graft Surgery: The MEND-CABG II Randomized Clinical Trial
Original Contributions Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
Marco Valgimigli; Gianluca Campo; Gianfranco Percoco; Leonardo Bolognese; Corrado Vassanelli; Salvatore Colangelo; Nicoletta de Cesare; Alfredo E. Rodriguez; Maurizio Ferrario; Raul Moreno; Tommaso Piva; Imad Sheiban; Giampaolo Pasquetto; Francesco Prati; Marco S. Nazzaro; Giovanni Parrinello; Roberto Ferrari; for the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators
JAMA 2008; 299: 1788-1799.
[Abstract][Full text][PDF]
